Company Overview and News

0
Aurobindo to acquire Apotex ops in 5 European nations for Euro 74 mn

2018-07-14 moneycontrol
Aurobindo Pharma today said it has inked a pact to acquire Apotex's commercial operations across five European countries, including Poland and Spain, for 74 million euros. The acquisition is in line with the company's strategy to strengthen and grow its European business and to expand in Eastern Europe, Aurobindo Pharma said in a statement.
AUROPHARMA 524804 ARBQY

0
Aurobindo to acquire Apotex operations in 5 European countries

2018-07-14 livemint
New Delhi: Aurobindo Pharma on Saturday said it has inked a pact to acquire Apotex’s commercial operations across five European countries, including Poland and Spain, for €74 million.
AUROPHARMA 524804 ARBQY

0
Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

2018-07-12 moneycontrol
As Indian drug makers brace to report their first-quarter earnings in the days ahead, analysts predict pharmaceutical companies to deliver strong performance in Q1FY19 helped by rebound of domestic formulation business on a base disrupted by GST last year and on currency tailwinds.
532321 AUROPHARMA 524804 ARBQY CDLYY CADILAHC

0
As trade war with US intensifies, China open doors to Indian pharmaceutical companies

2018-07-12 livemint
New Delhi: China is preparing to give swift regulatory approvals to India-manufactured drugs, the head of an Indian export promotion group said, as Beijing looks for new commercial partners ahead of what could be a protracted trade war with the United States.
524715 AUROPHARMA 524804 ARBQY SUNPHARMA

0
With United States trade under a cloud, China opens to Indian pharma

2018-07-12 moneycontrol
China is preparing to give swift regulatory approvals to India-manufactured drugs, the head of an Indian export promotion group said, as Beijing looks for new commercial partners ahead of what could be a protracted trade war with the United States
524715 AUROPHARMA 524804 ARBQY SUNPHARMA

0
Aurobindo Pharma gets USFDA nod for infection treatment drug

2018-07-11 moneycontrol
Drug firm Aurobindo Pharma has received final approval from the USFDA to manufacture and market Azithromycin tablets, used for the treatment of patients with mild to moderate infections, in the US market.
AUROPHARMA 524804 ARBQY

0
Aurobindo Pharma Limited - Press Release

2018-07-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AUROPHARMA 524804 ARBQY

43
Closing Bell: Global weakness drags Sensex 159 pts, Nifty below 10,700; Infosys, Titan up 2%

2018-07-02 moneycontrol
IPO: Bharat Hotels, which runs five-star properties under 'The LaLiT' brand, has filed draft prospectus with capital markets regulator to garner Rs 1,200 crore through its initial share-sale. The initial public offer (IPO) comprises sale of fresh equity shares to the tune of Rs 1,200 crore, according to the draft papers filed with the Securities and Exchange Board of India (Sebi). Proceeds of the issue will be utilised towards repayment of certain loans availed by the company for other general corporate purposes, reports PTI.
523405 500325 MS.PRE MS.PRF MS.PRG ICLQY MS.PRA 512599 CADILAHC 531795 JUSTDIAL 532321 LNSTY MS GODREJCP 500493 BHARATFORG JMFINANCIL RLNIY SBAZ ANNRY TVSMOTOR GRAPHITE 524804 505192 532822 532424 JSWSTEEL VED BATAINDIA MS.PRI MS.PRK 500180 SMLISUZU AUROPHARMA ADANIENT 500228 RELIANCE 512573 533155 JUBLFOOD GDRJY 532343 535648 RIGD JBLWY HDFCBANK 509488 INDIGO AVANTI IBN ATULAUTO CDLYY 539448 ICICIBANK HDB 532174 ARBQY IDEA 500043 JSTQY

37
Market Live: Sensex off day#39;s low; Infosys, ICICI Bank, Vedanta, Bajaj Auto top gainers

2018-07-02 moneycontrol
Buzzing: Graphite India and HEG shares prices were locked at 5 percent upper circuit each for the second consecutive session after Macquarie initiated coverage on both.
BAJAJ-AUTO 500325 AUROPHARMA RELIANCE MS.PRE MS.PRF MS.PRG 532977 MS.PRA 531795 532343 RIGD LNSTY HDFCBANK MS 500493 509488 BHARATFORG RLNIY SBAZ TVSMOTOR GRAPHITE 524804 IBN TATAPOWER ATULAUTO ICICIBANK VED MS.PRI MS.PRK HDB 532174 500180 ARBQY 500102 TPCL 500400 BALLARPUR

0
Aurobindo Pharma Limited - Press Release

2018-07-02 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
AUROPHARMA 524804 ARBQY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...